An early study identified seven SNPs of PI3K/PTEN/AKT/mTOR pathway in patients with advanced ESCC treated with 5-Fu, cisplatin or paclitaxel, and explored the association between clinical outcome and genetic variations. This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.